Who is affected by this change?

This affects Independence Blue Cross Hematology, Oncology, Rheumatology providers on Commercial plans.

When does this change take effect?

This change is effective Dec 10, 2025.

Back to dashboard

CommercialCoverageMedium impact

08.01.87a, Sutimlimab-jome (Enjaymo)

Independence Blue Cross·Hematology, Oncology, Rheumatology·Pharmacy

Effective date

Dec 10, 2025

We identified it

Jun 19, 2026

Days to comply

—

Summary

Insurance policy 08.01.87a for Sutimlimab-jome (Enjaymo) has been reissued with updates effective December 10, 2025. This is a pharmacy policy change that may affect coverage, prior authorization requirements, or billing procedures for this specialized medication.

Action Required

Action needed

Before December 10, 2025: Billing team should review the updated policy details at the provided URL to understand specific changes to Sutimlimab-jome (Enjaymo) coverage requirements. Update billing procedures and prior authorization workflows as needed based on the policy revisions.

Related policy hubs

Independence Blue Cross policies Hematology Oncology Rheumatology